The short version of gastric juice protein fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-22 and is reviewed periodically as new material appears.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentadecapeptide | Fifteen amino acids; sequence matches a fragment of a gastric juice protein |
| Molecular formula | C62H98N16O22 | Corresponds to a molecular mass near 1419 Da |
| Primary origin | Fragment of human gastric juice protein BPC | First characterized in the early 1990s |
| Common synonyms | BPC 157; PL 14736; pentadecapeptide BPC 157 | Naming conventions vary across publications |
| Reported stability | Stable in gastric juice during in vitro incubation | Based on laboratory incubation, not clinical data |
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
=== Abuse of migrants === According to Human Rights Watch, Houthi militias have "beaten, raped, and tortured detained migrants and asylum seekers from the Horn of Africa." UN experts have warned that female migrants face sexual violence, forced labor, and forced drug trafficking by smugglers who collaborate with the Houthi-controlled Yemen Immigration, Passport and Nationality Authority (IPNA).
== Science, technology and mathematics == Central limit theorem, in probability and statistics Construal level theory, a statistical social theory Central location test, a marketing research technique Cross-laminated timber, an engineered wood
== External links == Emil Fischer on Nobelprize.org including his Nobel Lecture Nobel Lecture, 12 December 1902 Syntheses in the Purine and Sugar Group Eminent Chemists of Our Time By Benjamin Harrow pages 216–239, published 1920 by Von Nostrand Company at books.google.com. Aders Plimmer, R. H. (July 1907). "The work of Emil Fischer and his school on the chemistry of the proteins". Science Progress in the Twentieth Century. 2 (5): 88–120. Guide to the Emil Fischer Papers at The Bancroft Library Text-book of Physiological Chemistry in Thirty Lectures by Emil Abderhalden, translated by William Thomas Hall and George Defren; published 1908 by Wiley Company, has many technical references to Fischer's work in Chemistry. American Journal of Diseases of Children 1911 volume 2 by the American Medical Association also refers to Fischer's work. An Introduction to the History of Medicine: With Medical Chronology by Fielding Hudson Garrison, page 708 refers to Fischer and Merings discovery of the drugs veronal(1904) and proponal(1905), published 1921 by Saunders Company. 1914 Year Book of the American Pharmaceutical Association, page 438 abstracts Fischer and Strauss's work on Phenol-Glucosides – Synthetic Production from Berlin d.D Chem. Germany, page 45(1912) No. 12. Texts on Wikisource: "Fischer, Emil". New International Encyclopedia. 1905. "Fischer, Emil". Encyclopædia Britannica (11th ed.). 1911. "Fischer, Emil". Encyclopedia Americana. 1920.
Sources: en.wikipedia.org
serious infections reactivation of hepatitis B reactivation of tuberculosis lethal hepatosplenic T-cell lymphoma (generally only when combined with 6-mercaptopurine) drug-induced lupus demyelinating central nervous system disorders psoriasis and psoriasiform skin lesions new-onset vitiligo Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia (some fatal) have been reported with infliximab. The FDA issued a warning to doctors appearing in the respective product labeling of infliximab instructing them to screen and monitor potential patients more carefully. The FDA issued a warning to doctors that there is an increased risk of lymphoma and other cancers associated with the use of infliximab and other tumor necrosis factor blockers in children and adolescents. Maintenance therapy with the drug (versus intermittent or sporadic therapy) lessens the likelihood of developing antibodies to infliximab which are known to reduce the efficacy of the drug. Combination treatment with methotrexate (an antifolate drug which suppresses the immune system) has been shown to reduce the formation of these antibodies in patients with rheumatoid arthritis and combination therapy with other immunosuppressants has been shown to reduce the likelihood of these antibodies being formed in Crohn's disease. The use of immunosuppressants may not be necessary in all diseases for which infliximab is indicated, and indiscriminant uses of these other immunosuppressants carry their own risks.
Health Canada has concluded that there is no health risk to Canadians from use of available soy and oyster sauces. Because continuous lifetime exposure to high levels of 3-MCPD could pose a health risk, Health Canada has established 1.0 part per million (ppm) as a guideline for importers of these sauces, in order to reduce Canadians' long-term exposure to this chemical. This is considered to be a very safe level.
Le Havre Octeville Airport which is located 5 km (3 mi) north of Le Havre at the town of Octeville-sur-Mer and managed by CODAH. The airport does not have any scheduled services to or from Le Havre at this time. Currently, air travel is served by the nearest Caen–Carpiquet Airport which is located approximately 54 km away from Le Havre. The main destination is the Transport hub of Lyon. Many holiday destinations are offered each year (Tunisia, Balearic Islands, Portugal, Greece, Bulgaria, etc.) through local travel agencies that charter aircraft. There is also the Flying club Jean Maridor at the airport. The Channel maritime links with Portsmouth in southern England with P&O Ferries ended on 30 September 2005 to be taken over by LD Lines who had changed the configuration. Two services to Portsmouth are provided daily from the Terminal de la Citadelle until ceasing operations in 2014, the route has since been taken over by Brittany Ferries. It will cease in September 2026. The link to Ireland was moved to the port of Cherbourg. Crossing times to Portsmouth vary from five hours and thirty minutes to eight hours. Popular alternative routes going to areas close to Le Havre include Newhaven to Dieppe, and Poole to Cherbourg.
Sources: en.wikipedia.org
=== 25th anniversary update === In November 2023, for the 25th anniversary of Half-Life, Valve updated the Steam version to revert content to its original 1998 state, fix long-standing bugs, and add content including the Half-Life: Uplink demo, four new multiplayer maps, Steam Deck support, rendering improvements, and support for 4K resolution monitors. Valve also released an hour-long documentary on the creation of Half-Life, featuring commentary from the original developers, designers and artists. Two days after the release, Half-Life reached 33,471 concurrent players on Steam, its highest-ever number.
== Classification == There are two subtypes of this receptor known at present, defined as CCKA and CCKB (also called CCK-1 and CCK-2, respectively). The CCKA receptor is mainly expressed in the small intestine, and is involved in the regulation of enzyme secretion by the pancreas, secretion of gastric acid in the stomach, intestinal motility and signaling of satiety (fullness). The CCKB receptor is expressed mainly in the central nervous system, and has functions relating to anxiety and the perception of pain. Antagonists for the CCK receptors can thus have multiple functions in both the gut and brain.
=== Hyperthermia === Hyperthermia is an elevation of body temperature over the temperature set point, due to either too much heat production or not enough heat loss. Hyperthermia is thus not considered fever. Hyperthermia should not be confused with hyperpyrexia (which is a very high fever). Clinically, it is important to distinguish between fever and hyperthermia as hyperthermia may quickly lead to death and does not respond to antipyretic medications. The distinction may however be difficult to make in an emergency setting, and is often established by identifying possible causes.
Republic of Armenia (former Armenian SSR) Republic of Georgia (former Georgian SSR) Republic of Moldova (former Moldavian SSR) Republic of Estonia (former Estonian SSR) Republic of Latvia (former Latvian SSR) Republic of Lithuania (former Lithuanian SSR)
Sources: en.wikipedia.org
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.
The letters abbreviate body protection compound, the name given to the parent protein isolated from gastric juice. The number is an identifier attached to the specific fragment, not a dose or a description of a chemical property.
The sequence corresponds to a segment of an endogenous gastric protein, but the isolated fifteen-amino-acid peptide is a synthetic construct. Whether the free fragment circulates in humans at measurable levels is not clearly established in the published literature.
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.